These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND POLE, POLE1, 5426, FLJ21434, DKFZp434F222, ENSG00000177084 AND Prognosis
27 results:

  • 1. pole-Mutant Colon Adenocarcinoma-Case Presentation and Histopathological Evaluation.
    Pancsa T; Vasas B; Melegh Z; Tóth E; Torday L; Sejben A
    J Gastrointest Cancer; 2024 Jun; 55(2):961-964. PubMed ID: 38175383
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Pan-cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancer.
    Zhong Y; Zheng C; Zhang W; Wu H; Wang M; Zhang Q; Feng H; Wang G
    Front Immunol; 2023; 14():1138077. PubMed ID: 37006282
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Genotype-Phenotype Correlations in Autosomal Dominant and Recessive APC Mutation-Negative colorectal Adenomatous Polyposis.
    Zhu LH; Dong J; Li WL; Kou ZY; Yang J
    Dig Dis Sci; 2023 Jul; 68(7):2799-2810. PubMed ID: 36862359
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
    Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
    Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
    Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. pole, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.
    Magrin L; Fanale D; Brando C; Fiorino A; Corsini LR; Sciacchitano R; Filorizzo C; Dimino A; Russo A; Bazan V
    Oncogene; 2021 Oct; 40(40):5893-5901. PubMed ID: 34363023
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer.
    Liu Z; Wang L; Guo C; Liu L; Jiao D; Sun Z; Wu K; Zhao Y; Han X
    J Cell Mol Med; 2021 Apr; 25(7):3239-3251. PubMed ID: 33624434
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. No evidence of EMAST in whole genome sequencing data from 248 colorectal cancers.
    Kondelin J; Martin S; Katainen R; Renkonen-Sinisalo L; Lepistö A; Koskensalo S; Böhm J; Mecklin JP; Cajuso T; Hänninen UA; Välimäki N; Ravantti J; Rajamäki K; Palin K; Aaltonen LA
    Genes Chromosomes Cancer; 2021 Jul; 60(7):463-473. PubMed ID: 33527622
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with pole mutations outside the exonuclease domain.
    Huang F; Tanaka H; Knudsen BS; Rutgers JK
    BMC Med Genet; 2020 Aug; 21(1):167. PubMed ID: 32838755
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles.
    Yan HHN; Siu HC; Ho SL; Yue SSK; Gao Y; Tsui WY; Chan D; Chan AS; Wong JWH; Man AHY; Lee BCH; Chan ASY; Chan AKW; Hui HS; Cheung AKL; Law WL; Lo OSH; Yuen ST; Clevers H; Leung SY
    Gut; 2020 Dec; 69(12):2165-2179. PubMed ID: 32217638
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and pole Exonuclease Domain Mutations.
    Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF
    Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with colorectal cancer.
    Salem ME; Battaglin F; Goldberg RM; Puccini A; Shields AF; Arguello D; Korn WM; Marshall JL; Grothey A; Lenz HJ
    Oncologist; 2020 May; 25(5):404-413. PubMed ID: 31848314
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
    Yang C; Austin F; Richard H; Idowu M; Williamson V; Sabato F; Ferreira-Gonzalez A; Turner SA
    Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604779
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
    IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
    Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. pole gene hotspot mutations in advanced pancreatic cancer.
    Guenther M; Veninga V; Kumbrink J; Haas M; Westphalen CB; Kruger S; Heinemann V; Kirchner T; Boeck S; Jung A; Ormanns S
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2161-2166. PubMed ID: 30194485
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
    Domingo E; Camps C; Kaisaki PJ; Parsons MJ; Mouradov D; Pentony MM; Makino S; Palmieri M; Ward RL; Hawkins NJ; Gibbs P; Askautrud H; Oukrif D; Wang H; Wood J; Tomlinson E; Bark Y; Kaur K; Johnstone EC; Palles C; Church DN; Novelli M; Danielsen HE; Sherlock J; Kerr D; Kerr R; Sieber O; Taylor JC; Tomlinson I
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):635-643. PubMed ID: 30042065
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Somatic pole exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
    Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
    J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Adjuvant Treatment for
    Van Gool IC; Rayner E; Osse EM; Nout RA; Creutzberg CL; Tomlinson IPM; Church DN; Smit VTHBM; de Wind N; Bosse T; Drost M
    Clin Cancer Res; 2018 Jul; 24(13):3197-3203. PubMed ID: 29559562
    [No Abstract]    [Full Text] [Related]  

  • 19. Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas.
    Zajac O; Raingeaud J; Libanje F; Lefebvre C; Sabino D; Martins I; Roy P; Benatar C; Canet-Jourdan C; Azorin P; Polrot M; Gonin P; Benbarche S; Souquere S; Pierron G; Nowak D; Bigot L; Ducreux M; Malka D; Lobry C; Scoazec JY; Eveno C; Pocard M; Perfettini JL; Elias D; Dartigues P; Goéré D; Jaulin F
    Nat Cell Biol; 2018 Mar; 20(3):296-306. PubMed ID: 29403038
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Somatic pole proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
    Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.